Download Files:
Tuvusertib
$170 – $1,280
Products Details
Product Description
– Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ[1].
Web ID
– HY-111451
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C16H12F2N8O
References
– [1]Nadia AHMAD, et al. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof. WO2015187451A1|[2]Lin Li, et al. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
CAS Number
– 1613200-51-3
Molecular Weight
– 370.32
Compound Purity
– 99.77
SMILES
– O=C(C1=C2N=CC(F)=CN2N=C1N)NC3=C(C4=CN=CN4C)C(F)=CN=C3
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 5 mg/mL (ultrasonic)
Target
– ATM/ATR
Pathway
– Cell Cycle/DNA Damage;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
